Market Overview

Eagle Pharma Has 'Several Upcoming Catalysts' And Is A Buy, RBC Says

Related EGRX
August PDUFA Dates: Biotech Investors Stay Tuned To A Month Of Plenty
Attention Biotech Investors: Keep Your Date With July PDUFA Action-Days
Notable earnings before Monday's open (Seeking Alpha)
Related TEVA
Outside Of Apple, Here Are 6 Other Stocks Warren Buffett Bought In Q4
How McKesson Will Stand The Test Of Amazon
Teva: Berkshire Thinks Bondholders Are 'Mullet Mullet' (Seeking Alpha)

Shares of Eagle Pharmaceuticals Inc (NASDAQ: EGRX) continue to rise on Monday, as they have been doing since the beginning of the year. Earlier this morning, RBC Capital Markets analysts Randall Stanicky and James C Chen initiated coverage on the stock with an Outperform rating and a $97.00 price target.

The experts recognize the intimidating power of the huge year-to-date stock price move. However, they believe “the value is real and there are several scenarios that can unlock more value.”

According to the research note, Bendamustine is key and is responsible for 54 percent of the equity value. However, RBC Capital Markets analysts also think there’s upside optionality. “While the stock is +442% YTD on the back of the Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) deal, we believe the contract terms leave upside scenarios for EGRX that could potentially deliver more over time,” they explained.

The experts also highlight the robustness of the company’s pipeline of additional opportunities, which they believe can help to support a maintainable growth story. The main near-term opportunity, they say, is EP-6101, an improved version of The Medicines Company (NASDAQ: MDCO)’s Angiomax.

Furthermore, Stanicky and Chen think expectations for Ryanodex -- for exertional heat stroke or EHS -- are generally low. However, this product is expected to be approved by mid-2017 and would be a first-to-market orphan drug.

Finally, the analysts see plenty of potential/a catalyst in expected near-term M&A activity on its sizable cash balance: “$116 million in cash, no debt, and an EBITDA base that beginning in 2016E will add further to cash and provide a base from which to lever up further.”

Check out RBC's estimates in the table below:

Source: RBC Capital Markets

Latest Ratings for EGRX

Jan 2017MizuhoDowngradesNeutralUnderperform
Nov 2016MizuhoUpgradesNeutralBuy
Nov 2016William BlairMaintainsOutperform

View More Analyst Ratings for EGRX
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas Health Care Price Target Initiation Analyst Ratings Movers


Related Articles (MDCO + EGRX)

View Comments and Join the Discussion!